Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;30(11):1516-1521.
doi: 10.1016/j.cardfail.2024.06.010. Epub 2024 Jul 11.

Prognostic Implications of Quantifying Vasoactive Medications in Cardiogenic Shock

Saraschandra Vallabhajosyula  1 , Anthony J Faugno  2 , Borui Li  2 , Kevin John  2 , Qiuyue Kong  2 , Shashank S Sinha  3 , Jaime Hernandez-Montfort  4 , Manreet K Kanwar  5 , Jacob Abraham  6 , Vanessa Blumer  3 , Maryjane Farr  7 , Justin Fried  8 , Arthur R Garan  9 , Shelley Hall  10 , Gavin W Hickey  11 , Rachna Kataria  1 , J U Kim  12 , Song Li  13 , Claudius Mahr  13 , Sandeep Nathan  14 , Mohit Pahuja  15 , Paavni Sangal  2 , Andrew Schwartzman  16 , VAN-Khue Ton  17 , Oleg A Vishnevsky  18 , Esther Vorovich  19 , Karol D Walec  2 , Peter Zazzali  2 , Elric Zweck  20 , Daniel Burkhoff  21 , Navin K Kapur  22
Affiliations

Prognostic Implications of Quantifying Vasoactive Medications in Cardiogenic Shock

Saraschandra Vallabhajosyula et al. J Card Fail. 2024 Nov.
No abstract available

Keywords: Cardiogenic shock, vasopressors; inotropes, pharmacological circulatory support, cardiac intensive care unit.

PubMed Disclaimer

Conflict of interest statement

Disclosures This work was supported by institutional grants from Abiomed, Boston Scientific, Abbott Laboratories, Getinge, and LivaNova to Tufts Medical Center. The sponsors had no input on the collection, analysis or interpretation of the data, nor in the preparation, review or approval of the manuscript. NKK has received consulting honoraria and institutional grant support from Abbott Laboratories, Abiomed, Boston Scientific, Medtronic, LivaNova, Getinge, and Zoll. MKK has served on the advisory board for Abiomed. SSS has served as a consultant for Abiomed. ARG has served as a consultant for NuPulseCV, has served on the scientific advisory board for Abiomed and is a recipient of research support from Verantos and Abbott. JH-M has served as a consultant for Abiomed. JA has served as a consultant for Abbott Laboratories and Abiomed. SN has received consulting honoraria from Abiomed, Getinge and CSI. SH has served as a consultant to Abiomed, Abbott and Medtronic. CM has served as a consultant to Abbott, Abiomed and Syncardia. DB has received an unrestricted, educational grant from Abiomed. All other authors report that they have no relationships relevant to the contents of this study to disclose.

LinkOut - more resources